Theravance Biopharma Files Definitive Proxy Statement

Ticker: TBPH · Form: DEF 14A · Filed: Apr 10, 2025 · CIK: 1583107

Theravance Biopharma, Inc. DEF 14A Filing Summary
FieldDetail
CompanyTheravance Biopharma, Inc. (TBPH)
Form TypeDEF 14A
Filed DateApr 10, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

TL;DR

Theravance Biopharma filed its proxy statement for the May 19th meeting. Get ready to vote.

AI Summary

Theravance Biopharma, Inc. filed its definitive proxy statement on April 10, 2025, for its annual meeting on May 19, 2025. The filing, under the 1934 Securities Exchange Act, details information for shareholders regarding the company's governance and upcoming votes. The company is based in George Town, Grand Cayman.

Why It Matters

This filing provides shareholders with crucial information to make informed decisions regarding company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine regulatory filing for an annual shareholder meeting, not indicating any immediate operational or financial distress.

Key Numbers

  • 1934 — SEC Act (Governing legislation for the filing)

Key Players & Entities

  • Theravance Biopharma, Inc. (company) — Registrant
  • 0001104659-25-033819 (filing_id) — Accession Number
  • 20250410 (date) — Filing Date
  • 20250519 (date) — Meeting Date
  • George Town, Grand Cayman (location) — Company Headquarters

FAQ

What is the purpose of a DEF 14A filing?

A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing detailed information about matters to be voted upon.

When is the Theravance Biopharma, Inc. annual meeting scheduled?

The annual meeting for Theravance Biopharma, Inc. is scheduled for May 19, 2025.

What is the filing date of this proxy statement?

This definitive proxy statement was filed on April 10, 2025.

Where is Theravance Biopharma, Inc. incorporated or headquartered?

Theravance Biopharma, Inc. is located at UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN.

What is the company's Standard Industrial Classification (SIC) code?

The SIC code for Theravance Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 10, 2025 regarding Theravance Biopharma, Inc. (TBPH).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.